CDH13

Across TCGA pan-cancer cohorts, CDH13 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDH13 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CDH13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDH13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

KIRP, UCEC, and ESCA are the cancer types where CDH13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.088	0.920	<.001	48	view →
UCEC	DFS	Median	All	1.000	0.821	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	21	view →
READ	DFS	Median	All	0.256	0.733	.018	9	view →
BLCA	OS	Median	IV	0.085	0.599	<.001	9	view →
LUAD	DFS	Median	II,III,IV	1.000	0.669	.034	4	view →
ACC	OS	Median	All	0.149	0.686	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDH13–KIRP (DFS)

Open the KIRP breakdown →